New pill shows promise for rare gut tumors

NCT ID NCT05077384

Completed Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a daily pill called surufatinib in 36 Japanese patients with neuroendocrine tumors that had stopped responding to other treatments. The goal was to see if the drug is safe and whether it can shrink tumors. The trial combined an early safety phase with a later phase measuring tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surufatinib (a drug taken by mouth once daily)
What this could lead to: If successful, surufatinib could offer a new treatment option for patients with neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase study with only 36 participants, so results may not apply broadly. Side effects are possible, and the drug may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS NON-HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

Aichi Cancer Centre

Nagoya, 464-8681, Japan
Fukuoka Sanno Hospital

Fukuoka, 814-0001, Japan
Hokkaido University Hospital

Sapporo, 060-8648, Japan
Kagawa University Hospital

Kagawa, 761-0793, Japan
Kansia Electric Power Hospital

Osaka, 553-0003, Japan
Kyorin University Hospital

Mitaka, 181-8611, Japan
Kyoto University Hospital

Kyoto, 606-8507, Japan
Kyushu University Hospital

Fukuoka, 812-0054, Japan
National Cancer Centre Hospital

Tokyo, 104-004, Japan
National Cancer Centre Hospital East

Kashiwa-shi, 277-8577, Japan
Tohoku University Hospital

Sendai, 890-8574,, Japan
Yokohama City University Hospital

Yokohama, 236-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.